PriceTargets.com logo

Medicenna Therapeutics - MDNA Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.75
  • Forecasted Upside: ∞
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 11/2/2023 12:59 AM ET
+0 (0.00%)
Get New Medicenna Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MDNA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MDNA

Analyst Price Target is $2.75
▲ +∞ Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Medicenna Therapeutics in the last 3 months. The average price target is $2.75, with a high forecast of $3.00 and a low forecast of $2.50. The average price target represents a ∞ upside from the last price of $0.00.

This chart shows the closing price for MDNA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Medicenna Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/23/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/19/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/19/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/14/2023OppenheimerLower TargetOutperform ➝ Outperform$8.00 ➝ $3.00Low
8/10/2023HC WainwrightReiterated RatingBuy ➝ Buy$2.50Low
7/31/2023HC WainwrightReiterated RatingBuy ➝ Buy$2.50Low
2/8/2023HC WainwrightReiterated RatingBuy$2.50Low
11/29/2022GuggenheimInitiated CoverageBuyLow
11/8/2022HC WainwrightLower TargetBuy$4.00 ➝ $2.50Low
8/16/2022HC WainwrightLower TargetBuy$5.00 ➝ $4.00Low
6/23/2022HC WainwrightReiterated RatingBuy$7.00 ➝ $5.00Low
6/22/2022OppenheimerLower TargetOutperform$12.00 ➝ $10.00Low
11/15/2021HC WainwrightReiterated RatingBuy$7.00Low
9/22/2021Bloom BurtonInitiated CoverageBuy$11.00Medium
6/1/2021HC WainwrightLower TargetBuy$8.00 ➝ $7.00High
12/17/2020OppenheimerInitiated CoverageOutperform$12.00High
9/10/2020HC WainwrightInitiated CoverageBuy$8.00Low
8/24/2020Brookline Capital ManagementReiterated RatingBuyMedium
8/24/2020Bloom BurtonReiterated RatingBuyMedium
(Data available from 4/18/2019 forward)

News Sentiment Rating

-0.66 (Sell)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2023
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
11/20/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/19/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
4/18/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Medicenna Therapeutics logo
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.29
Low: $0.16
High: $0.39

52 Week Range

Now: N/A

Volume

1,267,200 shs

Average Volume

160,047 shs

Market Capitalization

$10.93 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.3

Frequently Asked Questions

What sell-side analysts currently cover shares of Medicenna Therapeutics?

The following sell-side analysts have issued research reports on Medicenna Therapeutics in the last twelve months: HC Wainwright, and Oppenheimer Holdings Inc..
View the latest analyst ratings for MDNA.

What is the current price target for Medicenna Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Medicenna Therapeutics in the last year. Their average twelve-month price target is $2.75. Oppenheimer Holdings Inc. has the highest price target set, predicting MDNA will reach $3.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $2.50 for Medicenna Therapeutics in the next year.
View the latest price targets for MDNA.

What is the current consensus analyst rating for Medicenna Therapeutics?

Medicenna Therapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MDNA will outperform the market and that investors should add to their positions of Medicenna Therapeutics.
View the latest ratings for MDNA.

What other companies compete with Medicenna Therapeutics?

Other companies that are similar to Medicenna Therapeutics include RedHill Biopharma, Eterna Therapeutics, Purple Biotech, MIRA Pharmaceuticals and Elevai Labs. Learn More about companies similar to Medicenna Therapeutics.

How do I contact Medicenna Therapeutics' investor relations team?

Medicenna Therapeutics' physical mailing address is 200-1920 Yonge Street, Toronto A6, M4S 3E2. The company's listed phone number is (416) 648-5555 and its investor relations email address is [email protected]. The official website for Medicenna Therapeutics is www.medicenna.com. Learn More about contacing Medicenna Therapeutics investor relations.